Physician profile
Brian Sellers
NPI 1801916788
$71,166.20
in general payments reported to CMS, 2019-2025
31 companies · $5,468 in 2025
The $5,468 reported for 2025 was more than what 85% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $390 · 2021: $306 · 2022: $1,270 · 2023: $29K · 2024: $34K · 2025: $5,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $66K · Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $65,976.67 |
| Food and Beverage | $1,653.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $66,266.82 | 2023-2025 | Auryon Laser System 100-120 Vac, Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| Bard Peripheral Vascular, INC. | $1,155.67 | 2019-2022 | |
| Silk Road Medical, INC. | $959.44 | 2019 | |
| Medtronic, INC. | $794.96 | 2021-2025 | Endurant Iis, Heli-Fx Endoanchor System, Valiant Captivia |
| Philips North America LLC | $290.78 | 2019-2025 | IV Other, Igt Devices Systems Undivided |
| Janssen Pharmaceuticals, INC | $281.71 | 2019-2022 | |
| Endologix LLC | $235.71 | 2024 | Endocross Device, Torus Stent Graft System |
| Boston Scientific Corporation | $134.15 | 2019 | |
| Chiesi USA, INC. | $110.48 | 2019-2021 | |
| Pfizer INC. | $100.91 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $88.03 | 2019-2023 | Eliquis |
| Medtronic Vascular, INC. | $87.11 | 2019-2020 | |
| Kerecis Limited | $84.46 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Smith+Nephew, INC. | $79.64 | 2019-2025 | Collagenase Santyl |
| Abbott Laboratories | $75.28 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $56.90 | 2025 | Purified Cortrophin Gel |
| Cordis US Corp. | $47.49 | 2022 | |
| W. L. Gore & Associates, INC. | $47.05 | 2019 | |
| Getinge USA Sales, LLC | $45.32 | 2019-2021 | |
| Argon Medical Devices, INC. | $28.50 | 2019-2020 | |
| Amgen INC. | $25.21 | 2024 | Krystexxa |
| Organogenesis INC. | $22.32 | 2021 | |
| Ossur Americas, INC. | $21.07 | 2025 | |
| Terumo Medical Corporation | $20.00 | 2020 | |
| Ethicon US, LLC | $19.79 | 2024 | Dermabond Prineo, Surgiflo Hemostatic Matrix, Vistaseal |
| Paratek Pharmaceuticals, INC. | $18.58 | 2023 | Nuzyra |
| Bioventus LLC | $16.69 | 2025 | Exogen Ultrasound Bone Healing System |
| Csl Behring | $15.70 | 2019 | |
| Allergan, INC. | $14.16 | 2019 | |
| Tactile Systems Technology INC | $13.45 | 2022 | |
| Lemaitre Vascular, INC. | $8.82 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.